Israeli bio-med Aposense has successfully completed pre-clinical studies for the ATT-11T molecule for early stage treatment of colon cancer. ATT-11T works in tandem with Pfizer’s Camptosar (generic name Irinotecan) to improve its effectiveness with fewer side effects.
http://www.globes.co.il/serveen/globes/docview.asp?did=1000908249&fid=1725